

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

7

Application Number

10/506,592

Filing Date

September 3, 2004

First Named Inventor

Andrew David Morley

Art Unit

1615

Examiner Name

Not Yet Assigned

Attorney Docket Number

100659-1P US

**RECEIVED
CENTRAL FAX CENTER****FEB 17 2006****ENCLOSURES (Check all that apply)**

- ☐ Fee Transmittal Form
☐ Fee Attached
☐ Amendment/Reply
☐ After Final
☐ Affidavits/declaration(s)
☐ Extension of Time Request
☐ Express Abandonment Request
☐ Information Disclosure Statement
☐ Certified Copy of Priority Document(s)
☐ Reply to Missing Parts/ Incomplete Application
☐ Reply to Missing Parts under 37 CFR 1.52 or 1.53

- ☐ Drawing(s)
☐ Licensing-related Papers
☐ Petition
☐ Petition to Convert to a Provisional Application
☐ Power of Attorney, Revocation
☐ Change of Correspondence Address
☐ Terminal Disclaimer
☐ Request for Refund
☐ CD, Number of CD(s) _____
☐ Landscape Table on CD

- ☐ After Allowance Communication to TC
☐ Appeal Communication to Board of Appeals and Interferences
☐ Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
☐ Proprietary Information
☐ Status Letter
☒ Other Enclosure(s) (please identify below):
 Annotated Application Data Sheet
 Supplemental Application Data Sheet

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENTFirm Name
AstraZenecaSignature
*Lucy Padget*Printed name
Lucy Clare PadgetDate
FEB-17-06

Reg. No. L0074

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature
*Lucy Padget*Typed or printed name
Lucy Clare PadgetDate
February 17, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED
CENTRAL FAX CENTER

FEB 17 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/506,592	Applicant: Andrew David Morley
371 Filing Date: September 3, 2004	Attorney Docket No.: 100659-1P US
Examiner: Not yet assigned	Group Art Unit : 1615
Customer No.: 44992	Confirmation No.: 2926
Title: INDOLE-AMIDE DERIVATIVES AND THEIR USE AS GLYCOGEN PHOSPHORYLASE INHIBITORS	

I hereby certify that this correspondence is being facsimile
transmitted to the United States Patent and Trademark Office (571-
273-8300) on February 17, 2006

Signature
Lucy C. Padget

Mail Stop
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RE: SUPPLEMENTAL APPLICATION DATA SHEET

Sirs,

The Applicants submit herewith a Supplemental Application Data Sheet to amend inventorship details and correct a mistake in the parent application.


In addition to the above changes the Application Data Sheet now reflects the recent changes to the address for correspondence and representative information.

The Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No.: 100659-1P US.

AstraZeneca R&D Boston
A business unit of AstraZeneca Pharmaceuticals LP
35 Gatehouse Drive
Waltham MA 02451

Tel +1 781-839-4000
Fax +1 781-839-4500

Respectfully submitted,



Name: Lucy C. Padget
Dated: February 17, 2006
Reg. No.: L0074
Phone No.: 1 781 839 4182
Global Intellectual Property, Patents
AstraZeneca R&D Boston
35, Gatehouse Drive
Waltham, MA 02451

Enclosures: Annotated Application Data Sheet
Supplemental Application Data Sheet
Transmittal Form